AG
KRON

Artal Group’s Kronos Bio KRON Stock Holding History

Artal Group’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-842,954
Closed -$1.05M – 50
2024
Q2 		$1.05M Hold
842,954
– – 0.03% 89
2024
Q1 		$1.1M Hold
842,954
– – 0.03% 89
2023
Q4 		$1.05M Sell
842,954
-700,000
-45% -$775K 0.04% 72
2023
Q3 		$2.01M Hold
1,542,954
– – 0.09% 68
2023
Q2 		$2.65M Hold
1,542,954
– – 0.08% 80
2023
Q1 		$2.25M Hold
1,542,954
– – 0.13% 78
2022
Q4 		$2.5M Hold
1,542,954
– – 0.14% 80
2022
Q3 		$5.17M Hold
1,542,954
– – 0.22% 58
2022
Q2 		$5.62M Hold
1,542,954
– – 0.3% 54
2022
Q1 		$11.2M Hold
1,542,954
– – 0.47% 45
2021
Q4 		$21M Buy
1,542,954
+225,000
+17% +$3.52M 0.57% 45
2021
Q3 		$27.6M Hold
1,317,954
– – 0.62% 37
2021
Q2 		$31.6M Hold
1,317,954
– – 0.64% 34
2021
Q1 		$38.6M Hold
1,317,954
– – 0.68% 32
2020
Q4 		$39.4M Buy
+1,317,954
New +$41.3M 0.85% 32

Other funds holding KRON

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.83B AUM 20.31% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Artal Group's KRON Position: Q3 2024 in Review

Artal Group sold out of Kronos Bio (KRON) in Q3 2024, closing a stake of 842,954 shares — an estimated $1.05M sold.

Artal Group first reported a position in KRON in Q4 2020 and held it in 15 quarters. The position peaked at $39.4M in Q4 2020. 53 funds tracked by Wall St. Rank hold KRON as of Q3 2024.

  • Artal Group reported no remaining Kronos Bio position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 842,954 Kronos Bio shares in Q3 2024, an estimated $1.05M.
  • Artal Group first reported a position in Kronos Bio in Q4 2020 and held it in 15 quarters.
  • Artal Group's Kronos Bio position peaked at $39.4M in Q4 2020.
  • 53 funds tracked by Wall St. Rank held Kronos Bio as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.